What's behind Moderna's latest 14.1% stock surge?

Traders Union
All News
Stocks
Moderna surges 14.12% today on vaccine news

Highlights

Moderna and Merck announced their personalized mRNA cancer vaccine with Keytruda met the primary endpoint in a Phase 3 melanoma trial.
This clinical win could signal a strategic shift toward oncology for Moderna, which recently cut its workforce by 10% after lower COVID-19 vaccine sales.
Shares of Moderna trade in a strong bullish structure above major moving averages, with an expected five-day price range of $121.72 to $182.58 and upward move probability at 74%.

Oncology pivot emerges as trial win offsets declining covid business

On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran (mRNA-4157), combined with Keytruda, achieved the primary endpoint in a Phase 3 trial by significantly reducing melanoma recurrence. This trial marks Moderna’s first late-stage clinical victory beyond infectious diseases and may signal a strategic shift toward oncology for the company. Moderna has not issued a regular cash dividend since its IPO and recently reduced its workforce by 10% following weaker COVID-19 vaccine demand.

Anton Kharitonov, expert at Traders Union, notes Moderna's impressive 14.12% rally is technically driven but highlights extreme overbought signals. He points out the stock is trading well above all major moving averages, yet recent news flow likely induced speculative excess. The relative strength index (RSI) near 70 and a strong sell from the Stochastic RSI raise red flags for short-term traders. Sustained volatility and recent layoffs indicate underlying operational pressures that could cap further upside. "Despite the short-term hype, a pullback toward $150.7 or lower cannot be ruled out amid ongoing overextension and fundamental risks," says Kharitonov.

Viktoras Karapetjanc, expert at Traders Union, sees Moderna entering a new growth phase after its successful Phase 3 cancer vaccine trial with Merck. He emphasizes that victory in late-stage oncology trials is a structural breakthrough, supporting long-term investor confidence. Forward momentum is strong with all technicals pointing up, and the bullish structure remains intact above $150. Karapetjanc expects further growth as the company pivots beyond infectious diseases. "There are clear opportunities ahead for bulls — I believe a confirmed break above $176.66 could spark a fresh wave of institutional inflows," he notes.

Sholanke Dele, market strategist, views the price spike as driven by short-term sentiment following positive trial news. He notes the outsized daily gain and high volatility indicate heightened risk of sharp reversals. Dele warns that the absence of regular dividends and recent workforce reductions reflect lingering business uncertainties. "Investors should exercise caution — without consistent earnings strength, such rallies can quickly lose steam," says Dele.

Bullish alignment and overbought signals heighten volatility risk

Moderna is trading above all major moving averages, with the current price at $152.15 well above the MA-20 ($68.02), MA-50 ($65.62), and MA-200 ($48.13). This positioning confirms a strong bullish structure across short-, medium-, and long-term timeframes, supported by a bullish alignment between MA-50 and MA-200. Immediate focus is on the near-term ceiling at $176.66 and the near-term floor at the intraday high of $150.7. Momentum signals remain positive, with the MACD and Average Directional Index (ADX) both forecasting buy readings. The Relative Strength Index (RSI) is elevated at 69.43 (buy), and the Commodity Channel Index (CCI) and Bull/Bear Power (BBP) both show extreme overbought conditions. Stochastic RSI, however, diverges with a strong sell signal, highlighting caution on stretched intraday momentum. Buyers are dominating intraday price action (BBP at 65.42), but the daily change of $18.83 (up 14.12%) after an upside gap of $16.68 (12.51%) leaves the price near session highs and volatility at 16.93%. Intraday tone is strong with persistent upward pressure, but oscillators warn of overextended conditions.

Previously it was reported that Moderna's bullish technical setup was challenged by extreme volatility following profit-taking despite significant advancements in its cancer vaccine pipeline. The latest breakout confirms strengthened upward momentum but given heightened overbought signals, sustained price action above the $176.66 resistance remains essential to validate the current bullish scenario and avoid a reversal toward the recent volatility range.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.